



Panion: Change in number of shares in Panion Animal Health AB (publ)

The issuance of units with pre-emption rights has been fully registered with the Swedish Companies Registration Office. Due to the registration the share capital has increased by SEK 5,486.208556 and the number of shares and the number of votes has increased by 117,720. Through the issuance of units with pre-emption rights the share capital has in total increased by SEK 211,176.713085 and the number of shares and the number of votes has increased by 4,531,312.

The conversion of SEK 2,300,000 of the convertible notes to shares, issued under the financing arrangement between Panion Animal Health AB and an investment fund managed by Yorkville Advisors Global announced on 9 January 2018, has also been registered with the Swedish Companies Registration Office. The number of convertible notes converted was 23. The number of convertible notes remaining under the first tranche for future conversion is 0. Through the conversion the number of shares and the number of votes has increased by 2,196,360. The total number of shares and the total number of votes after the conversion amount to 1,074,784.327522. The total share capital after the conversion amounts to 23,062,122.

Anja E. H. Holm, CEO + 45-22 94 66 00 anja.holm@panion-animalhealth.com




Ánja E. H. Holm, CEO | +45-22 94 66 00 anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at Spotlight Stock Market.

Panion Animal Health AB

info@panion-animalhealth.com

linkedin.com/company/panion-animalhealth







panion-animalhealth.com